Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.355 USD | +0.08% | -4.93% | +1.29% |
04-19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
04-01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 59% by 2026.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- The company has insufficient levels of profitability.
- The company is highly valued given the cash flows generated by its activity.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.29% | 194M | B- | ||
+25.66% | 681B | C+ | ||
+21.85% | 556B | B | ||
-5.22% | 361B | C+ | ||
+17.12% | 325B | B- | ||
+4.60% | 285B | C+ | ||
+13.40% | 235B | B+ | ||
+3.61% | 199B | B- | ||
-11.21% | 189B | A+ | ||
-4.06% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LFCR Stock
- Ratings Lifecore Biomedical, Inc.